Heat Biologics (HTBX) Announces Topline Data from HS-110 Phase 1b in NSCLC; Notes Strong OS for Immune Responders
Tweet Send to a Friend
Heat Biologics, Inc. (Nasdaq: HTBX) reported topline response and survival results in the ongoing Phase 1b study evaluating HS-110, in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
